PZM21 (1) was recently reported as a biased agonist of the mu-opioid receptor (MOR) with improved antinociceptive effects and reduced side effects compared with traditional opioid-based analgesics. The original synthesis of PZM21 with the desired (S,S) configuration required the separation of a diastereomeric mixture in the final step by using chiral HPLC. A concise synthesis of 1 has now been developed in the enantiomeric pure form starting with commercially available l-alanine and proceeding via a chiral aziridine as a key intermediate. The final product was obtained as the (S,S) diastereomer in seven steps in 22.5% yield from l-alanine. This synthetic strategy could be readily applied to the development of PZM21 analogues at the thiophenyl position.
Synthesis of enantiopure PZM21
A biased agonist of the mu-opioid receptor
Perrey, D., Zhang, D., Nguyen, T., Carroll, F. I., Ko, M-C., & Zhang, Y. (2018). Synthesis of enantiopure PZM21: A biased agonist of the mu-opioid receptor. European Journal of Organic Chemistry, (29), 4006-4012. https://doi.org/10.1002/ejoc.201800517
To contact an RTI author, request a report, or for additional information about publications by our experts, send us your request.
Multifaceted risk for non-suicidal self-injury only versus suicide attempt in a population-based cohort of adults
Long-term effects of a diet supplement containing Cannabis sativa oil and Boswellia serrata in dogs with osteoarthritis following physiotherapy treatments
The importance of quality data to track global progress in addressing stillbirths and neonatal mortality